Skip NavigationSkip to Content

Recent developments in animal venom peptide nanotherapeutics with improved selectivity for cancer cells

  1. Author:
    Giribaldi,Julien
    Smith,Jennifer
    Schroeder,Christina
  2. Author Address

    NCI, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
    1. Year: 2021
    2. Date: Sep-Oct
    3. Epub Date: 2021 05 11
  1. Journal: Biotechnology advances
  2. PERGAMON-ELSEVIER SCIENCE LTD,
    1. 50
  3. Type of Article: Review
  4. Article Number: 107769
  5. ISSN: 0734-9750
  1. Abstract:

    Animal venoms are a rich source of bioactive peptides that efficiently modulate key receptors and ion channels involved in cellular excitability to rapidly neutralize their prey or predators. As such, they have been a wellspring of highly useful pharmacological tools for decades. Besides targeting ion channels, some venom peptides exhibit strong cytotoxic activity and preferentially affect cancer over healthy cells. This is unlikely to be driven by an evolutionary impetus, and differences in tumor cells and the tumor microenvironment are probably behind the serendipitous selectivity shown by some venom peptides. However, strategies such as bioconjugation and nanotechnologies are showing potential to improve their selectivity and potency, thereby paving the way to efficiently harness new anticancer mechanisms offered by venom peptides. This review aims to highlight advances in nano- and chemotherapeutic tools and prospective anti-cancer drug leads derived from animal venom peptides.

    See More

External Sources

  1. DOI: 10.1016/j.biotechadv.2021.107769
  2. PMID: 33989705
  3. WOS: 000672159700009

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel